“A new drug for targeted etiotropic therapy of COVID-19 based on nirmatrelvir and ritonavir, created by Promomed Group of Companies using a unique technology, received a registration certificate on April 21, 2022,” TASS said in a statement.
On April 1, the Russian Ministry of Health registered the world's first nasal vaccine against COVID-19.
Gunzburg reported that the nasal vaccine against coronavirus has already entered civilian circulation.